Mechanisms of action of topical 5-fluorouracil: Review and implications for the treatment of dermatological disorders

References

• Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663–666.
   PubMed Web of Science ®Google Scholar
• Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48:381–395.
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–338.
   PubMed Web of Science ®Google Scholar
• Moore AY. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. J Dermatolog Treat. 2009;20(6):328–335.
   PubMed Web of Science ®Google Scholar
• Goette DK. Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol. 1981;4:633–649.
   PubMed Web of Science ®Google Scholar
• Sachs DL, Kang S, Hammerberg C, Helfrich Y, Karimipour D, Orringer J, Topical fluorouracil for actinic keratoses and photoaging: A clinical and molecular analysis. Arch Dermatol. 2009;145:659–666.
   PubMedGoogle Scholar
• Rutman RJ, Cantarow A, Paschkis KE. Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. Cancer Res. 1954;14:119–123.
   PubMed Web of Science ®Google Scholar
• Duschinsky R, Pleven E. The synthesis of 5-fluoropyrimidines. J Am Chem Soc. 1957;79:4559–4560.
   Web of Science ®Google Scholar
• Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16:215–237.
   PubMed Web of Science ®Google Scholar
• Klein E, Helm F, Milgrom H, Stoll HL Jr, Traenkle HL. Tumors of the skin. II. Keratoacanthoma; local effect of 5-fluorouracil. Skin (Los Angeles). 1962;1:153–156.
   PubMedGoogle Scholar
• Goldman L. The response of skin cancer to topical therapy with 5-fluorouracil. Cancer Chemother Rep. 1963;28:49–52.
   PubMedGoogle Scholar
• Dillaha CJ, Jansen GT, Honeycutt WM, Bradford AC. Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol. 1963;88:247–256.
   PubMed Web of Science ®Google Scholar
• Snyderman RK, Starzynski TE. Treatment of skin cancers and keratoses with 5-fluorouracil. Acta Chir Plast. 1968;10:181–187.
   PubMedGoogle Scholar
• Wohlhueter RM, McIvor RS, Plagemann PG. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol. 1980;104:309–319.
   PubMed Web of Science ®Google Scholar
• Yoshioka A, Tanaka S, Hiraoka O, Koyama Y, Hirota Y, Ayusawa D, Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem. 1987;262:8235–8241.
   PubMed Web of Science ®Google Scholar
• Mitrovski B, Pressacco J, Mandelbaum S, Erlichman C. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells. Cancer Chemother Pharmacol. 1994;35:109–114.
   PubMed Web of Science ®Google Scholar
• Aherne GW, Hardcastle A, Raynaud F, Jackman AL. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Biochem Pharmacol. 1996;51:1293–1301.
   PubMed Web of Science ®Google Scholar
• Ghoshal K, Jacob ST. Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res. 1994;54:632–636.
   PubMed Web of Science ®Google Scholar
• Patton JR. Ribonucleoprotein particle assembly and modification of U2 small nuclear RNA containing 5-fluorouridine. Biochemistry. 1993;32:8939–8944.
   PubMed Web of Science ®Google Scholar
• Doong SL, Dolnick BJ. 5-Fluorouracil substitution alters pre-mRNA splicing in vitro. J Biol Chem. 1988;263:4467–4473.
   PubMed Web of Science ®Google Scholar
• Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15–16.
   PubMed Web of Science ®Google Scholar
• Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, Maxwell PJ, The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res. 2002;62:2644–2649.
   PubMed Web of Science ®Google Scholar
• Ju J, Schmitz JC, Song B, Kudo K, Chu E. Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells. Clin Cancer Res. 2007;13:4245–4251.
   Google Scholar
• Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999;104:263–269.
   PubMed Web of Science ®Google Scholar
• McNutt NS, Saenz-Santamaria C, Volkenandt M, Shea CR, Albino AP. Abnormalities of p53 protein expression in cutaneous disorders. Arch Dermatol. 1994;130:225–232.
   PubMedGoogle Scholar
• Fluoroplex [package insert]. Irvine, CA: Allergan, Inc.; 2004.
   Google Scholar
• Efudex [package insert]. Costa Mesa, CA: Valeant Pharmaceuticals North America; 2005.
   Google Scholar
• Carac [package insert]. Bridgewater, NJ: Dermik Laboratories; August 2009.
   Google Scholar
• Levy S, Furst K, Chern W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin Ther. 2001;23:901–907.
   PubMed Web of Science ®Google Scholar
• Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24:990–1000.
   PubMed Web of Science ®Google Scholar
• Dillaha CJ, Jansen GT, Honeycutt WM, Holt GA. Further studies with topical 5-fluorouracil. Arch Dermatol. 1965;92:410–417.
   PubMed Web of Science ®Google Scholar
• Erlanger M, Martz G, Ott F, Storck H, Rieder J, Kessler S. Cutaneous absorption and urinary excretion of 6-14C-5-fluorouracil ointment applicated in an ointment to healthy and diseased human skin. Dermatologica. 1970;140(suppl I):7–14.
   Google Scholar
• Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5:2006–2011.
   PubMed Web of Science ®Google Scholar
• Torres A. Non-surgical approaches to non-melanoma skin cancer. Presented at the Winter Clinical Dermatology Conference, 23–28 January 2010, Koloa, HI.
   Google Scholar
• Eaglstein WH, Weinstein GD, Frost P. Fluorouracil: Mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol. 1970;101:132–139.
   PubMedGoogle Scholar
• Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis – A systematic review of randomized controlled trials. Int J Dermatol. 2009;48:453–463.
   PubMed Web of Science ®Google Scholar
• Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: A randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140:813–816.
   PubMedGoogle Scholar
• Marrero GM, Katz BE. The new fluor-hydroxy pulse peel. A combination of 5-fluorouracil and glycolic acid. Dermatol Surg. 1998;24:973–978.
   PubMed Web of Science ®Google Scholar
• Ditre CM. The treatment of photodamaged skin with 5% 5-fluorouracil peels. Cosmet Dermatol. 2007;20:568–572.
   Google Scholar
• Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: Efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007;33:433–440.
   PubMed Web of Science ®Google Scholar
• Mohs FE, Jones DL, Bloom RF. Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma. Arch Dermatol. 1978;114:1021–1022.
   PubMedGoogle Scholar
• Gray RJ, Meland NB. Topical 5-fluorouracil as primary therapy for keratoacanthoma. Ann Plast Surg. 2000;44:82–85.
   PubMed Web of Science ®Google Scholar
• Yuge S. Keratoacanthoma centrifugum marginatum: Response to topical 5-fluorouracil. J Am Acad Dermatol. 2006;54:S218–S219.
   Google Scholar
• Hadley JC, Tristani-Firouzi P, Florell SF, Bowen GM, Hadley ML. Case series of multiple recurrent reactive keratoacanthomas developing at surgical margins. Dermatol Surg. 2009;35:2019–2024.
   PubMed Web of Science ®Google Scholar
• Ondo AL, Mings SM, Pestak RM, Shanler SD. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol. 2006;55:1092–1094.
   PubMed Web of Science ®Google Scholar
• Price NM. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. J Drugs Dermatol. 2007;6:778–781.
   PubMedGoogle Scholar
• Gibbs S, Harvey I. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2006;3:CD001781.
   Google Scholar
• Salk RS, Grogan KA, Chang TJ. Topical 5% 5-fluorouracil cream in the treatment of plantar warts: A prospective, randomized, and controlled clinical study. J Drugs Dermatol. 2006;5:418–424.
   PubMedGoogle Scholar
• De Jong EM, Menke HE, van Praag MC, van de Kerkhof PC. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: A double-blind study. Dermatology. 1999;199:313–318.
   PubMed Web of Science ®Google Scholar
• Falkson G, Schulz EJ. Skin changes in patients treated with 5-fluorouracil. Br J Dermatol. 1962;74:229–236.
   PubMed Web of Science ®Google Scholar